FOLH1 and prostate cancer: In prostate cancer patients, common imaging modalities include MRI, transrectal ultrasound, conventional CT, cone-beam CT, and molecular imaging, often in the form of PET/CT with tracers such as radiolabeled Prostate-Specific Membrane Antigen (PSMA) and fluorine-labeled 18F-choline [4].